Christopher James Roberts - 18 Mar 2026 Form 3 Insider Report for AC Immune SA (ACIU)

Reporting relationship
Chief Financial Officer
Issuer ticker
ACIU
Reported as of
18 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 13:09:22 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Matthias Maurer, attorney-in-fact for Christopher James Roberts

Key filing fact

Christopher James Roberts filed Form 3 for AC Immune SA (ACIU) on 18 Mar 2026.

Key facts

  • This page summarizes Christopher James Roberts's Form 3 filing for AC Immune SA (ACIU).
  • 0 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 13:09.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002112626 Primary reporting owner

Roberts Christopher James

Relationship
Chief Financial Officer
Address
EPFL INNOVATION PARK, BUILDING B, LAUSANNE, SWITZERLAND
Signature
/s/ Matthias Maurer, attorney-in-fact for Christopher James Roberts
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACIU holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
155,382
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
7,200
Exercise price
$5.15
Footnotes
F2
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
7,200
Exercise price
$6.30
Footnotes
F2
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
7,200
Exercise price
$6.88
Footnotes
F2
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
7,200
Exercise price
$2.76
Footnotes
F2
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
29,126
Exercise price
$2.32
Footnotes
F2
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
55,215
Exercise price
$3.99
Footnotes
F3
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
92,308
Exercise price
$2.91
Footnotes
F4
ACIU holding Derivative

Share Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Common Shares
Underlying amount
89,552
Exercise price
$3.03
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Includes 109,564 common shares underlying outstanding restricted share units.

Footnote F2

The share option is fully vested.

Footnote F3

The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2024.

Footnote F4

The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2025.

Footnote F5

The share option vests in twelve substantially equal quarterly installments beginning on March 31, 2026.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .